Lopez-Cortes, Luis FTrujillo-Rodriguez, MariaBaez-Palomo, AliciaBenmarzouk-Hidalgo, Omar JDominguez-Molina, BeatrizMilanes-Guisado, YusnelkisEspinosa, NuriaViciana, PompeyoGutierrez-Valencia, Alicia2023-01-252023-01-252018-08-15López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, Benmarzouk-Hidalgo OJ, Dominguez-Molina B, Milanés-Guisado Y, et al. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018 Jul 13;218(4):624-632.http://hdl.handle.net/10668/12696There are contradictory data about the influence that hepatitis C virus (HCV) has on immune activation and inflammation in patients coinfected with human immunodeficiency virus (HIV) and HCV. HIV/HCV-coinfected patients receiving antiretroviral treatment who achieved a sustained virological response with interferon-free regimens were consecutively enrolled in a prospective study. The following factors were assessed before, immediately after the end of, and 1 month after the end of therapy: expression of HLA-DR/CD38, PD-1, and CD57 on CD4+ and CD8+ T-cells; measurement of the total HIV DNA load in peripheral blood mononuclear cells; and determination of plasma levels of soluble CD14 (sCD14), lipopolysaccharide (LPS), 16S ribosomal DNA (rDNA), interleukin 6 (IL-6), D-dimers, and high-sensitivity C-reactive protein (hsCRP). Ninety-seven patients were consecutively included. At the end of therapy and 1 month later, there were significant reductions in the expression of HLA-DR and CD38 in CD4+ and CD8+ T cells, as well as levels of proviral HIV DNA, sCD14, LPS, 16S rDNA, and D-dimer (P HCV eradication in HIV/HCV-coinfected patients results in significant decreases in levels of immune activation markers, proviral HIV DNA load, microbial translocation markers, and D-dimers. These findings support the use of HCV treatment for all HIV/HCV-coinfected patients, even those with low-grade fibrosis.enBacterial TranslocationAntiviral AgentsHIVHumansProspective StudiesSustained Virologic ResponseTreatment OutcomeViral LoadBiomarkersCoinfectionFemaleHIV InfectionsHepatitis C, ChronicImmunologic FactorsMaleMiddle AgedRNA, BacterialRNA, Ribosomal, 16ST-Lymphocytesresearch article29986086Restricted AccessPacientesADN RibosómicoReceptores de LipopolisacáridosLinfocitos TInterferonesHepacivirusDiagnósticoLipopolisacáridosInflamaciónFibrosis10.1093/infdis/jiy1361537-6613https://academic.oup.com/jid/article-pdf/218/4/624/25160485/jiy136.pdf